Uncertainties in Screening and Prevention of Group B Streptococcus Disease

Clin Infect Dis. 2019 Aug 1;69(4):720-725. doi: 10.1093/cid/ciy1069.


In autumn 2016, the UK Department of Health (now Department of Health and Social Care) convened 2 meetings to discuss how to address research evidence gaps in order to minimize the impact of infant group B streptococcus (GBS) disease in the United Kingdom. At that meeting, a number of research priorities were highlighted, including improving the screening for GBS colonization in pregnant women, offering intrapartum antibiotic prophylaxis and point-of-care testing, and understanding the effect of widespread intrapartum antibiotic use on long-term infant health. Further discussions involved investigating the feasibility of a large prospective study of pregnant women and their infants in order to understand the role of antibodies in the protection against GBS disease in infancy following maternal exposure to GBS colonization. Here, we summarize the research uncertainties identified at that meeting.

Keywords: group B streptococcus; maternal; neonatal; screening; vaccine.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Antibiotic Prophylaxis
  • Carrier State / diagnosis
  • Carrier State / drug therapy
  • Female
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Pregnancy
  • Pregnancy Complications, Infectious* / diagnosis
  • Pregnancy Complications, Infectious* / drug therapy
  • Pregnancy Complications, Infectious* / prevention & control
  • Streptococcal Infections* / diagnosis
  • Streptococcal Infections* / drug therapy
  • Streptococcal Infections* / prevention & control
  • Streptococcus agalactiae*
  • United Kingdom


  • Anti-Bacterial Agents